Lizzy241/BobWayne, Agree 100% on your insights here!
One hopes that Denner understands the importance of getting
AMRN acquired by BP as quickly as possible so that BP can get
in position to right the ship and rev up the sales engine.
AMRN has messed up almost every opportunity they have had to
salvage their position. With each poor decision comes negative
consequences for the company which management takes no meaningful
responsibility for creating. As much as I hope KM will be able
salvage the situation, so far I do not see it. KM's talks in what
to me seem empty platitudes with no substance behind his plans.
Horrific to see such a great drug demonized by certain interests
without being aggressively defended by the company. Horrific not
just from the shareholders losses but the continued lack of understanding
about the benefits of Vascepa to CVD patients and their doctors.
The public today, and their doctors seem to have no faith in credible
scientific information regarding the drugs effectiveness. Seems that
any positive message is always muddled with old, incorrect, and disproven
propaganda from idiots like Nissen. The sooner a BP such as JNJ or PFE
takes the helm, the sooner these idiotic notions will be laid to rest!
Market Data 
Markets 
AI
